Press
Press
BioInnovation Institute Boilerplate
ENG: At BioInnovation Institute (BII), we accelerate world-class life science start-up innovation to benefit people and society. As a non-profit institute, BII operates the company creation programs, Bio Studio Venture Lab, and Venture House, to support life science start-ups with knowledge, network, infrastructure, and funding of up to 3M EUR per project and 1,8 M EUR per start-up. With our expertise, network, funding, and infrastructure, we empower startups to succeed and believe in the transformative power of life science innovation. Read more on www.bii.dk.
DA: BioInnovation Institute (BII) har en mission om at støtte tidlige start-ups og translationelle forskningsprojekter i at kommercialisere deres ideer til gavn for mennesker og samfundet som helhed. BII er en nonprofit-fond, der driver tre forskellige programmer: Bio Studio, Venture Lab og Venture House. Alle tre programmer har til formål at bringe videnskaben tættere på markedet og accelerere innovation inden for life science. BII fokuserer primært på at støtte start-ups og projekter, der har potentiale til at løse problemer relateret til planetens eller menneskers sundhed.
BII har omfattende viden om forretningsudvikling og et stort investornetværk samt en unik infrastruktur, der giver adgang til højteknologiske laboratorier. Alt dette bidrager til at skabe de bedste rammebetingelser for, at start-ups og translationelle forskningsprojekter kan opnå succes. Besøg BII’s hjemmeside på www.bii.dk for mere information.
Get to know BII
Research ideas often fail to mature into products and solutions that reach the market due to a lack of suitable facilities, experienced personnel, and access to finance. To address this, the Novo Nordisk Foundation established BioInnovation Institute (BII) in 2017 to advance research, innovation, and entrepreneurship within the life sciences.
BII offers early-stage funding, business development support, lab- and office infrastructure, and a global network for start-ups and translational projects in its portfolio. The aim is to help entrepreneurs develop and mature their research projects to the point where they can attract crucial capital investment and thus contribute to developing new solutions within planetary and human health.
In 2021, the BioInnovation Institute became an independent commercial foundation with a non-profit objective.
About BII's Programs
Learn more about our Venture Lab program.
ENG: BII’s Venture Lab program supports early-stage start-ups in their journey from cutting-edge, transformative ideas into start-ups ready for market. The program combines business acceleration, scientific development, and team development and includes a EUR 500,000 risk-free convertible loan. During the program, start-ups conduct key experiments to reach initial proof of concept and receive valuable help to make a business plan and set up a team that will allow them to progress rapidly toward the market.
DA: BIIs Venture Lab program støtter virksomheder i deres rejse fra banebrydende idéer til start-ups, der er klar til at komme på markedet. Programmet består af en katalyserende combination af forretningsudvikling, videnskabelig modning og teamudviling og tilbyder tilmed et risikofrit konvertibelt lån på ca DKK 4M. I programmet udfører virksomhederne nøgleeksperimenter, der hjælper dem med at validere deres idé, og modtager værdifuld hjælp til at bygge en forretningsplan og sammensætte et kompetent team, der kan få dem på markedet hurtigst muligt.
Learn more about our Bio Studio program.
ENG: BII’s Bio Studio program supports world-leading entrepreneurial Principal Investigators (PIs) in translating their science into innovative products and solutions. It is specifically designed to support innovative projects originating from universities, hospitals, and/or other research institutes. The ambition of the program is to build and run a leading life science company creation facility in Europe with 15-20 projects working to translate their science into new solutions at full capacity.
DA: BIIs Bio Studio program støtter verdens førende forskere i at omsætte deres videnskab til innovative produkter og løsninger. Det er specielt designet til at støtte innovative projekter, der stammer fra universiteter, hospitaler og/eller andre forskningsinstitutter. Programmets ambition er at opbygge og drive et førende center for life science virksomhedsdannelse i Europa, som ved fuld kapacitet vil inkubere 15-20 projekter, der arbejder på at oversætte deres forskning til nye løsninger.
Executive Leadership Team Press Photos
Do you need a photo of a member of BII’s leadership team? Click here to access a folder with both print and web-quality photos.
When using our pictures, please credit BioInnovation Institute or Esben Zøllner Olesen.
BII Domicile Press Photos
Do you need a photo of the BII domicile? Click here to access a folder with both print and web-quality photos.
When using our pictures, please credit BioInnovation Institute or Esben Zøllner Olesen.
BII Logo Package
Do you need BII’s logo for your website, a slide deck, or something else? Click here to access it. Please contact Anders Mønsted before using BII’s logo in any external materials.
The purpose of BII is to operate an incubator to accelerate world-class life science innovation that drives the development of new solutions by early life science start-ups for the benefit of people and society.
BII is not an investor. BII provides its start-ups and projects with financial support either through convertible loans, as is the case for start-ups in the Venture Lab program, or through grants, as is the case for projects in the Bio Studio project.
A convertible loan note is a type of short-term debt that may be converted into equity shares at a later date based on predefined terms. The loan includes no personal guarantees of repayment from the founders. In case of liquidation (company closure), the unrepaid balance of the loan may be converted into a grant from BII.
The convertible loan is paid in one tranche upon project initiation after agreement of milestones to be reached. These can be a mix of technical, commercial, and team development milestones. The convertible loan note must be signed by the company, the founders of the company, and the existing shareholders in the company.
BII is a non-profit enterprise foundation established in 2021 with financial support from the Novo Nordisk Foundation of up to EUR 470 million over 10 years.
No, BII is an independent non-profit enterprise foundation. BII is currently financed by a grant from the Novo Nordisk Foundation of up to EUR 470M over 10 years.